Literature DB >> 9579640

Comparative in vitro investigation of prothrombin complex concentrates.

J Römisch1, K Bonik, H G Müller.   

Abstract

Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the products. Neither free thrombin nor elevated levels of activated FX were detected. In contrast, analyses of FVIIa, of residual amidolytic activities, and of concentrations of unwanted ingredients demonstrated considerable differences between the products. While antithrombin III was detected only in two of three concentrates, heparin was found in all PCCs but in markedly different concentrations. Although the homogeneity of the products has been clearly improved in comparison with former comparative investigations, the products can be distinguished by their compound profile and by a couple of in vitro assays.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579640     DOI: 10.1055/s-2007-995838

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  7 Procoagulators.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 2.  Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

Authors:  Benny Sørensen; Donat R Spahn; Petra Innerhofer; Michael Spannagl; Rolf Rossaint
Journal:  Crit Care       Date:  2011-01-12       Impact factor: 9.097

3.  Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.

Authors:  Oliver Grottke; Rolf Rossaint; Yvonne Henskens; Rene van Oerle; Hugo Ten Cate; Henri M H Spronk
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.